Literature DB >> 11744077

Recent developments in structure-activity relationships for steroid modulators of GABA(A) receptors.

D F Covey1, A S Evers, S Mennerick, C F Zorumski, R H Purdy.   

Abstract

GABAergic neurotransmission can be both positively and negatively modulated by steroids. The steroid effects are thought to be mediated by binding of steroids to specific sites on GABA(A) receptors. It appears that the receptor sites for positive and negative modulatory steroids are different. Thus far, the location and number of binding sites for steroids on these receptors have not been established. In this brief review, we concentrate largely on results from our own structure-activity studies. Novel analogues have been studied to further delineate the structural features required for compounds to modulate receptor function via steroid binding sites. Non-naturally occurring enantiomers of both positive and negative modulators have been studied to provide further evidence for the existence of specific steroid binding sites on the receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11744077     DOI: 10.1016/s0165-0173(01)00126-6

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  17 in total

Review 1.  Fast nongenomic effects of steroids on synaptic transmission and role of endogenous neurosteroids in spinal pain pathways.

Authors:  Rémy Schlichter; Anne Florence Keller; Mathias De Roo; Jean-Didier Breton; Perrine Inquimbert; Pierrick Poisbeau
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 2.  NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders.

Authors:  Charles F Zorumski; Yukitoshi Izumi
Journal:  Neurosci Biobehav Rev       Date:  2012-01-02       Impact factor: 8.989

3.  A predicted binding site for cholesterol on the GABAA receptor.

Authors:  Jérôme Hénin; Reza Salari; Sruthi Murlidaran; Grace Brannigan
Journal:  Biophys J       Date:  2014-05-06       Impact factor: 4.033

4.  A neurosteroid analogue with T-type calcium channel blocking properties is an effective hypnotic, but is not harmful to neonatal rat brain.

Authors:  N Atluri; S M Joksimovic; A Oklopcic; D Milanovic; J Klawitter; P Eggan; K Krishnan; D F Covey; S M Todorovic; V Jevtovic-Todorovic
Journal:  Br J Anaesth       Date:  2018-02-09       Impact factor: 9.166

Review 5.  Structure-activity relationship studies on neuroactive steroids in memory, alcohol and stress-related functions: a crucial benefit from endogenous level analysis.

Authors:  Monique Vallée
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

6.  Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS against Aβ₂₅₋₃₅ peptide-induced toxicity in vitro and in vivo in mice.

Authors:  Fadia El Bitar; Johann Meunier; Vanessa Villard; Marion Alméras; Kathiresan Krishnan; Douglas F Covey; Tangui Maurice; Yvette Akwa
Journal:  Psychopharmacology (Berl)       Date:  2014-01-31       Impact factor: 4.530

7.  Neurosteroid Analogues. 13. Synthetic methods for the preparation of 2beta-hydroxygonane derivatives as structural mimics of ent-3alpha-hydroxysteroid modulators of GABA(A) receptors.

Authors:  Cunde Wang; Nigam P Rath; Douglas F Covey
Journal:  Tetrahedron       Date:  2007-08-13       Impact factor: 2.457

8.  A 17beta-derivative of allopregnanolone is a neurosteroid antagonist at a cerebellar subpopulation of GABA A receptors with nanomolar affinity.

Authors:  G Maksay; L Fodor; T Bíró; N Avlonitis; T Calogeropoulou
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

Review 9.  Mechanisms of neurosteroid interactions with GABA(A) receptors.

Authors:  Gustav Akk; Douglas F Covey; Alex S Evers; Joe Henry Steinbach; Charles F Zorumski; Steven Mennerick
Journal:  Pharmacol Ther       Date:  2007-04-20       Impact factor: 12.310

Review 10.  Neurosteroids, stress and depression: potential therapeutic opportunities.

Authors:  Charles F Zorumski; Steven M Paul; Yukitoshi Izumi; Douglas F Covey; Steven Mennerick
Journal:  Neurosci Biobehav Rev       Date:  2012-10-17       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.